|Purity||>95% by SDS PAGE|
Recombinant SARS-CoV-2 RBD domain with C-terminal His-tag, expressed into periplasm of E. coli.
The spike (S) glycoprotein of coronaviruses mediates binding and entry of the virus into the host cell. The S protein is also a major immunogen and a target for development of antiviral drugs. The spike protein is a transmembrane protein composed of two subunits, S1 and S2. The S1 subunit contains a receptor-binding domain (RBD) responsible for binding to the receptor angiotensin-converting enzyme 2 (ACE2). Several mutants of the spike protein has been identified so far with various affinity to ACE2 and changed immunogenicity.
ELISA, Western blot, LIA, Protein arrays
500 ug/mL, 10mM Tris pH 7.5, 50mM KCl
RBD domain of the Spike protein (AA 319-541) from original Wuhan-Hu-1 isolate (NC_045512). The N501Y mutation is characteristic for all three of the currently observed fast spreading SARS-CoV-2 virus variants B.1.1.7, B.1.351 and P1. The mutation K417N is characteristic for the fast spreading SARS-CoV-2 virus variant B.1.351 emerged in South Africa.
-80°C. Aliquot upon arrival.
For research use only. Not for use in diagnostic procedures.